Please ensure Javascript is enabled for purposes of website accessibility

2 Reasons Why This FDA Decision Could Add Billions to Regeneron's Revenue

By Adria Cimino - Jun 12, 2021 at 6:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

They have to do with production -- and delivery to the patient.

The U.S. Food and Drug Administration granted Regeneron Pharmaceuticals' (REGN -0.22%) antibody treatment for the coronavirus authorization late last year. Unlike coronavirus vaccines, the product hasn't yet brought in billions of dollars in revenue. Regeneron reported $262 million in sales of REGEN-COV in the first quarter. And the product hasn't inspired major share gains either. Regeneron shares have increased about 5% year to date.

A new FDA decision, however, could accelerate the REGEN-COV success story. The regulatory agency last week authorized a lower dose of the antibody cocktail. And the authorization includes a change in delivery method. Regeneron now can deliver the treatment by subcutaneous injection. Originally, the authorization only covered administration by infusion. Why do these details matter? Let's take a look at two reasons why the recent regulatory decision could equal billions for Regeneron.

An investor reads something on their cell phone.

Image source: Getty Images.

1. More product ready for delivery

The U.S. government back in January increased its order for Regeneron's antibody cocktail, asking for an additional 1.25 million doses. This new order represents $2.63 billion in revenue -- if Regeneron can deliver. (The government previously offered the company a $450 million contract for the supply of 300,000 doses.)

When Regeneron announced the January deal, it expected to produce 750,000 doses by the June 30 deadline. At that point, the cocktail only was authorized at the 2,400 mg dose level. Now that the FDA has given the nod to a 1,200 mg dose, Regeneron can produce more doses more quickly, because less product is needed for each dose.

Here's how that translates into a win for Regeneron: The biotech company says that at the lower dose level it should be able to deliver at least 1 million doses. The government may accept additional doses through Sept. 30.

So, it seems very likely Regeneron can produce and deliver the full number of doses -- and benefit from the highest level of revenue possible from this contract. And that's thanks to the lower dose. This dose level also will help Regeneron manufacture more product more quickly for other customers. And importantly, less product per treatment -- half of the original dose -- should lower costs over time.

2. A path to widespread use

A major hurdle for companies making antibody treatments for COVID-19 has been the delivery method: typically by infusion in a healthcare setting.

This has meant two challenges. The first is from the professional side of things. Hospitals, overwhelmed with coronavirus patients, sometimes don't have the resources to maintain infusion centers for antibody treatments. This requires space and staff. The second point has to do with patients. Since antibodies are meant for mild to moderate cases, some patients haven't felt ill enough to take the step to go for treatment. They know the administration of infusions involves spending 20 minutes to about an hour in a healthcare setting.

"Unfortunately, to date only a fraction of patients eligible for antibody treatments have received them, which we hope will change based on this updated FDA authorization," George D. Yancopoulos, Regeneron's chief scientific officer, said when announcing the new authorization.

Injections don't require infusion centers -- or a lot of time for administration. That's good news for healthcare providers and patients. This should increase use of Regeneron's antibody cocktail. The more the treatment is used, the more governments will be willing to make bigger orders in the future. That means more revenue for Regeneron.

Regeneron's annual revenue has generally been on the rise for the past decade. And annual profit tops $3.5 billion.

REGN Net Income (Annual) Chart

REGN Net Income (Annual) data by YCharts

The company commercializes seven other products, including blockbuster eye drug Eylea. The new authorization of REGEN-COV adds the possibility of another billion-dollar product to the mix. Regeneron shares may not surge overnight on this news. But for the two reasons above and the company's product portfolio, Regeneron shares are a good bet for long-term investors.

Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Regeneron Pharmaceuticals, Inc. Stock Quote
Regeneron Pharmaceuticals, Inc.
REGN
$613.61 (-0.22%) $-1.35

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
377%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/08/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.